000250 — Sam Chun Dang Pharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- KR₩211bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.52 | ||
| Price to Tang. Book | 23.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.8 | ||
| EV to EBITDA | 287.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.61% | ||
| Return on Equity | -4.49% | ||
| Operating Margin | 1.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 166,862.33 | 167,274.9 | 177,335.41 | 192,668.52 | 210,923.8 | n/a | n/a | 2.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Directors
- Dae Yin Yoon CHM (63)
- Jeon Gyo Park CCE (59)
- Dae Wuk Kim MDR (57)
- Tae Eun Jang OTH (51)
- Geon Jung Hwang OTH (60)
- Hyeong Gyun Jeon OTH (52)
- Gwang Jin Yim OTH (56)
- Gi Jong Hong NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 29th, 1943
- Public Since
- October 4th, 2000
- No. of Shareholders
- 63,099
- No. of Employees
- 364
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 23,257,472
- Address
- 71, Jeyakgongdan 2-gil, Hyangnam-eup, HWASEONG, 18622
- Web
- http://www.scd.co.kr/
- Phone
- +82 220461100
- Auditors
- Sunjin Accounting Corp.
Upcoming Events for 000250
Q2 2025 Sam Chun Dang Pharm Co Ltd Earnings Release
Similar to 000250
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Sam Chun Dang Pharm Co share price?
As of Today at 23:01 UTC, shares in Sam Chun Dang Pharm Co are trading at KR₩143,300. This share price information is delayed by 15 minutes.
How has the Sam Chun Dang Pharm Co share price performed this year?
Shares in Sam Chun Dang Pharm Co last closed at KR₩143,300 and the price had moved by +36.77% over the past 365 days. In terms of relative price strength the Sam Chun Dang Pharm Co share price has outperformed the FTSE Developed Asia Pacific Index by +38.33% over the past year.
What are the analyst and broker recommendations for Sam Chun Dang Pharm Co?
The overall consensus recommendation for Sam Chun Dang Pharm Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sam Chun Dang Pharm Co dividend yield?
The Sam Chun Dang Pharm Co dividend yield is 0.14% based on the trailing twelve month period.
Does Sam Chun Dang Pharm Co pay a dividend?
Last year, Sam Chun Dang Pharm Co paid a total dividend of KR₩200, and it currently has a trailing dividend yield of 0.14%. We do not have any data on when Sam Chun Dang Pharm Co is to next pay dividends.
When does Sam Chun Dang Pharm Co next pay dividends?
We do not have data on when Sam Chun Dang Pharm Co is to next pay dividends. The historic dividend yield on Sam Chun Dang Pharm Co shares is currently 0.14%.
How do I buy Sam Chun Dang Pharm Co shares?
To buy shares in Sam Chun Dang Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sam Chun Dang Pharm Co?
As of the previous close price of KR₩143,300, shares in Sam Chun Dang Pharm Co had a market capitalisation of KR₩3tn.
Where are Sam Chun Dang Pharm Co shares listed?
Here are the trading details for Sam Chun Dang Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 000250
What kind of share is Sam Chun Dang Pharm Co?
Based on an overall assessment of its quality, value and momentum Sam Chun Dang Pharm Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sam Chun Dang Pharm Co share price forecast for 2025?
The analyst consensus target price for shares in Sam Chun Dang Pharm Co is KR₩63,689. That is 55.56% below the last closing price of KR₩143,300.
Analysts covering Sam Chun Dang Pharm Co currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Sam Chun Dang Pharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sam Chun Dang Pharm Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +20.52%.
As of the last closing price of KR₩143,300, shares in Sam Chun Dang Pharm Co were trading -7.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sam Chun Dang Pharm Co PE Ratio?
The Sam Chun Dang Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩143,300.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sam Chun Dang Pharm Co?
Sam Chun Dang Pharm Co's management team is headed by:
- Dae Yin Yoon - CHM
- Jeon Gyo Park - CCE
- Dae Wuk Kim - MDR
- Tae Eun Jang - OTH
- Geon Jung Hwang - OTH
- Hyeong Gyun Jeon - OTH
- Gwang Jin Yim - OTH
- Gi Jong Hong - NID